Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

The machine learning life cycle and the cloud: implications for drug discovery

Open access
Spjuth, Ola, Frid, Jens, Hellander, Andreas · 2021 · Expert Opinion on Drug Discovery

Abstract

Introduction: Artificial intelligence (AI) and machine learning (ML) are increasingly used in many aspects of drug discovery. Larger data sizes and methods such as Deep Neural Networks contribute to challenges in data management, the required software stack, and computational infrastructure. There is an increasing need in drug discovery to continuously re-train models and make them available in production environments.Areas covered: This article describes how cloud computing can aid the ML life cycle in drug discovery. The authors discuss opportunities with containerization and scientific workflows and introduce the concept of MLOps and describe how it can facilitate reproducible and robust ML modeling in drug discovery organizations. They also discuss ML on private, sensitive and regulated data.Expert opinion: Cloud computing offers a compelling suite of building blocks to sustain the ML life cycle integrated in iterative drug discovery. Containerization and platforms such as Kubernetes together with scientific workflows can enable reproducible and resilient analysis pipelines, and the elasticity and flexibility of cloud infrastructures enables scalable and efficient access to compute resources. Drug discovery commonly involves working with sensitive or private data, and cloud computing and federated learning can contribute toward enabling collaborative drug discovery within and between organizations.Abbreviations: AI = Artificial Intelligence; DL = Deep Learning; GPU = Graphics Processing Unit; IaaS = Infrastructure as a Service; K8S = Kubernetes; ML = Machine Learning; MLOps = Machine Learning and Operations; PaaS = Platform as a Service; QC = Quality Control; SaaS = Software as a Service

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17460441.2021.1932812

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 55 · Cited by 67

Research works printed but not linked: 2

  1. Gudivada V, Apon A, Ding J. Data quality considerations for big data and machine learning: going beyond data cleaning and transformations. Int J Adv Software. 2017;10:1–20.
  2. 10.1038/s41592-020-01023-0 · DOI

Metadata

Authors
Spjuth, O., Frid, J., & Hellander, A.
Affiliations
  • Uppsala University (SE)
  • Scaleout Systems AB
Corresponding author
Spjuth, Ola
Venue
Expert Opinion on Drug Discovery
Published
2021-05-31
Volume
16
Issue
9
Pages
1071-1079
ISSN
  • 1746-0441 (ISSN-L)
  • 1746-045X
OpenAlex
W3165081806
Cited by
67
References
55
Citations by year
2026: 11 · 2025: 14 · 2024: 19 · 2023: 13 · 2022: 7 · 2021: 3
FWCI
5.51
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Drug Discovery (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
FORMAS
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Social Sciences › Decision Sciences › Information Systems and Management › Scientific Computing and Data Management
  • Physical Sciences › Computer Science › Information Systems › Cloud Computing and Resource Management
Keywords
machine learning lifecycle, cloud computing, drug discovery, MLOps, containerization, Kubernetes, scientific workflows, reproducibility, model retraining, private data, sensitive data, federated learning, data management, IT infrastructure
MeSH terms
Cloud Computing, Machine Learning, Animals, Artificial Intelligence, Humans, Life Cycle Stages, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The machine learning life cycle and the cloud: implications for drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2021.1932812
The paper
Spjuth, O., Frid, J., & Hellander, A. (2021). The machine learning life cycle and the cloud: implications for drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2021.1932812

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.